GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (OTCPK:LVCLY) » Definitions » Current Ratio

Algorae Pharmaceuticals (Algorae Pharmaceuticals) Current Ratio : 26.76 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Algorae Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Algorae Pharmaceuticals's current ratio for the quarter that ended in Dec. 2023 was 26.76.

Algorae Pharmaceuticals has a current ratio of 26.76. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Algorae Pharmaceuticals's Current Ratio or its related term are showing as below:

LVCLY' s Current Ratio Range Over the Past 10 Years
Min: 3.33   Med: 9.88   Max: 26.84
Current: 26.84

During the past 13 years, Algorae Pharmaceuticals's highest Current Ratio was 26.84. The lowest was 3.33. And the median was 9.88.

LVCLY's Current Ratio is ranked better than
96.14% of 1554 companies
in the Biotechnology industry
Industry Median: 3.79 vs LVCLY: 26.84

Algorae Pharmaceuticals Current Ratio Historical Data

The historical data trend for Algorae Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Current Ratio Chart

Algorae Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.33 9.87 6.12 17.86 9.35

Algorae Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.80 17.86 - 9.35 26.76

Competitive Comparison of Algorae Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, Algorae Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algorae Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Current Ratio falls into.



Algorae Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Algorae Pharmaceuticals's Current Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Current Ratio (A: Jun. 2023 )=Total Current Assets (A: Jun. 2023 )/Total Current Liabilities (A: Jun. 2023 )
=2.823/0.302
=9.35

Algorae Pharmaceuticals's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=2.515/0.094
=26.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algorae Pharmaceuticals  (OTCPK:LVCLY) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Algorae Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Algorae Pharmaceuticals (Algorae Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (Algorae Pharmaceuticals) Headlines